The historical term neuroleptics refers to drugs now more correctly termed antipsychotics. In depression they do not constitute a class of antidepressants and should not be interpreted as drugs generically intended to increase dopaminergic transmission. Their role depends on the clinical presentation: some second generation antipsychotics can be used as adjunctive treatment in major depressive disorder after an insufficient response to an antidepressant, some have efficacy and specific indications in bipolar depression, while in psychotic depression the combination of an antidepressant with an antipsychotic is a reference pharmacological strategy.
The three situations are not interchangeable. A patient with a nonpsychotic unipolar major depressive episode, a patient with bipolar disorder in a depressive phase, and a patient with major depression accompanied by delusions or hallucinations have different diagnoses, prognoses and therapeutic rationales. Before using an antipsychotic, it is therefore necessary to define the diagnosis precisely, verify the adequacy of previous treatments, exclude pseudoresistance due to insufficient dose, duration or adherence, and assess the balance between expected benefit and metabolic, neurological, endocrine and cardiovascular risks.
The strongest evidence in major depressive disorder concerns some second generation antipsychotics and cannot be extended to the entire class. Regulatory status also differs among molecules, formulations and countries. In Italy, some extended release formulations of quetiapine have an indication for adjunctive treatment of major depressive episodes in MDD after a suboptimal response to antidepressant monotherapy; aripiprazole has international evidence as augmentation in MDD, but this indication does not appear in the current Italian SmPCs for ABILIFY reviewed for this article. The distinction between scientific evidence and authorized indication is essential when discussing off label use.
Second generation antipsychotics are pharmacologically heterogeneous. Their clinical activity derives from interaction with dopaminergic, serotonergic, adrenergic, histaminergic and, for some molecules or metabolites, monoamine transporter systems. There is therefore no single “antidepressant mechanism of antipsychotics”. The benefit observed with augmentation probably arises from coordinated modulation of multiple cortical and limbic circuits, but does not demonstrate a simple dopaminergic or serotonergic deficit underlying depression.
Aripiprazole is a partial agonist at D2, D3 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. In the presence of high dopaminergic tone, its partial agonism can produce a functionally antagonistic effect, while in other circuits it may preserve some dopaminergic signaling. This profile helps explain the relative rarity of hyperprolactinemia compared with purer D2 antagonists, but does not eliminate the risk of extrapyramidal effects: in antidepressant augmentation, akathisia is one of the most clinically relevant adverse events.
Quetiapine has 5-HT2A and D2 antagonism, as well as H1 and alpha1 adrenergic activity that contribute to sedation and orthostatic hypotension. Its active metabolite norquetiapine has additional properties, including inhibition of the norepinephrine transporter and activity at 5-HT1A receptors. The pharmacology explains why the effect at very low doses is dominated by sedation, whereas therapeutic action in mood disorders requires studied dosage regimens and cannot be equated with occasional use as a hypnotic.
Olanzapine is a multireceptor antagonist with high affinity for serotonergic, dopaminergic, muscarinic and histaminergic receptors. It is an effective antipsychotic, but its metabolic profile limits use when alternatives with a more favorable benefit risk balance exist. Increased appetite, weight, triglycerides and blood glucose can be substantial and require continuous comparison of psychiatric benefit with the individual's cardiometabolic risk.
Amisulpride is a benzamide with predominantly D2/D3 activity and additional properties described at the 5-HT7 receptor. At low doses it has been studied mainly in dysthymia and persistent depressive presentations in older trials. These data do not make it a contemporary standard treatment for major depressive disorder. Even low doses can substantially increase prolactin because tuberoinfundibular D2 blockade is clinically relevant.
Levosulpiride, the active enantiomer of sulpiride with D2 activity and also used in gastroenterology, has a much more limited historical psychiatric literature than drugs currently recommended in international guidelines. The existence of older antidepressant studies does not justify using it as an equivalent alternative to better validated augmentation strategies. Potential endocrine and extrapyramidal effects also remain relevant.
The general principle is therefore molecule specificity: efficacy, dose, formulation, authorization, interactions and adverse events must be assessed for the individual drug. It is not scientifically correct to transfer a benefit demonstrated for quetiapine or aripiprazole to all antipsychotics, nor to assume that a sedating dose is automatically an antidepressant dose.
In nonpsychotic major depressive disorder, an antipsychotic is considered mainly when an adequately selected antidepressant taken at a therapeutic dose and for an adequate duration has produced an insufficient response. Before defining depression as treatment resistant, diagnosis, adherence, episode duration, psychiatric and medical comorbidities, substance use disorder, concomitant medications and the possibility that the presentation belongs to the bipolar spectrum should be reassessed. Pharmacological augmentation does not correct an incorrect diagnosis or an antidepressant treatment that was never truly adequate.
Guidelines and meta analyses of augmentation strategies show that some second generation antipsychotics can increase the probability of response or remission compared with continuation of the antidepressant plus placebo. The average benefit, however, must be interpreted together with a higher frequency of discontinuation for adverse events and very different tolerability profiles. Antipsychotic augmentation is therefore an individualized choice, not a mandatory step after every partial response.
Extended-release quetiapine is particularly relevant in Italy because some AIFA SmPCs include adjunctive treatment of major depressive episodes in patients with MDD who have had a suboptimal response to antidepressant monotherapy. In the current SmPCs reviewed, titration for this indication is 50 mg/day on days 1 and 2 and 150 mg/day on days 3 and 4; in clinical studies, an antidepressant effect was observed at 150 and 300 mg/day. The dose should nevertheless be individualized and kept at the minimum effective level, with particular attention to sedation, hypotension, weight gain and metabolic abnormalities.
Aripiprazole is supported by numerous international trials and meta analyses as an adjunct to an antidepressant in MDD with insufficient response. It is often considered when limiting sedation and metabolic burden relative to olanzapine or quetiapine is desirable, but this relative advantage does not mean neutral tolerability. Akathisia, restlessness, insomnia, nausea and, less frequently, other extrapyramidal effects can make treatment unacceptable. In the current Italian AIFA SmPCs for aripiprazole reviewed, indications concern schizophrenia and bipolar I disorder, not adjunctive treatment of MDD; in Italy, any antidepressant use therefore requires a prescribing assessment consistent with regulations governing off label use.
Olanzapine has evidence as a component of combination strategies, but in nonpsychotic unipolar depression its use must be weighed against one of the highest propensities for weight gain and metabolic dysfunction among second generation antipsychotics. The fixed olanzapine fluoxetine combination has specific indications in the United States, but this should not be presented as a generalizable Italian authorization. Olanzapine monotherapy is not a standard antidepressant treatment for unipolar MDD.
The choice between antipsychotic augmentation and other strategies, such as switching antidepressants, combining antidepressants, lithium, structured psychotherapy or somatic treatments, depends on the number and quality of previous trials, severity, suicide risk, presence of psychotic or catatonic symptoms, comorbidities and patient preferences. In severe or complex presentations, treatment sequencing should be managed in specialist care.
Response should be measured using explicit clinical criteria. If no meaningful benefit emerges after an adequate period at a therapeutic dose, continuing an antipsychotic indefinitely exposes the patient to risks without clinical justification. Even when the drug is effective, the need to maintain augmentation should be periodically reassessed, and any dose reduction should be planned to avoid abrupt discontinuation and confusion between withdrawal symptoms and relapse.
Psychotic depression is a major depressive episode in which delusions and/or hallucinations occur. It is more severe than nonpsychotic depression and requires particular attention to suicidality, refusal of food or fluids, immobility, catatonia, impaired judgment and capacity for self care. Psychotic symptoms may be mood congruent or mood incongruent and should be distinguished from schizoaffective disorder, bipolar disorder, a primary psychotic disorder and organic or medication related causes.
According to NICE, for depression with psychotic symptoms, combination of an antidepressant and an antipsychotic, for example olanzapine or quetiapine, should be considered with specialist monitoring. Available evidence supports combination treatment over the antipsychotic component alone in several studies, but does not demonstrate that a single antipsychotic is universally superior to all others. The choice should therefore integrate efficacy data, previous response, metabolic risk, extrapyramidal effects, QT, prolactin, sedation and interactions.
The STOP-PD study demonstrated that, in patients with psychotic depression, the combination sertraline plus olanzapine produced higher remission rates than olanzapine plus placebo. The subsequent STOP-PD II study showed that in patients in remission, continuing olanzapine together with sertraline reduced relapse risk compared with discontinuing olanzapine, although at the cost of additional metabolic adverse effects. These data support combination treatment and the need not to discontinue the antipsychotic automatically as soon as psychotic symptoms disappear.
The optimal duration of antipsychotic treatment after remission is not identical for everyone. It should consider the number of episodes, severity of psychosis, speed of remission, tolerability, previous relapses after discontinuation and ability to monitor. NICE suggests considering continuation of the antipsychotic for several months after remission, with shared decision making and, ideally, specialist involvement.
In cases of imminent suicide risk, severe somatic compromise, catatonia, refusal of food or a need for a very rapid response, electroconvulsive therapy may play a central role. The availability of pharmacological treatment should not delay appropriate somatic treatment when clinical severity requires it.
Once the acute phase has resolved, the diagnosis should be reviewed longitudinally. Emergence of mania or hypomania, a strongly suggestive family history or compatible previous episodes may reclassify the presentation as bipolar disorder, substantially changing the maintenance strategy and the role of antidepressants.
Bipolar depression is not a variant of unipolar depression, and pharmacological selection must begin with recognition of the bipolar disorder. A history of manic or hypomanic episodes, episodic course, family history, early onset and compatible clinical features should be sought before intensifying antidepressant therapy. The goal is to treat the depressive phase without increasing the risk of switching, mood instability or cycling.
Quetiapine has established evidence in bipolar depression and is authorized in Italy for treatment of major depressive episodes associated with bipolar disorder. Italian SmPCs specify a titration schedule for this indication and a therapeutic dose distinct from merely sedative use. Response and tolerability should be reassessed because somnolence, hypotension, weight gain and metabolic abnormalities can limit continuation.
Olanzapine is effective mainly for mania and prevention of recurrences in patients who responded during the manic phase; its position in the treatment of bipolar depression varies among guidelines and jurisdictions. In the United States, the olanzapine fluoxetine combination is authorized for bipolar depression, but this does not amount to an Italian indication for olanzapine alone in a depressive episode.
Aripiprazole is effective in treating mania and preventing manic recurrences in specific settings, but monotherapy studies in acute bipolar depression did not support sufficient antidepressant efficacy to make it a standard treatment for the depressive episode. It is therefore incorrect to infer from its role in bipolar disorder that it is automatically indicated in every phase of the illness.
Treatment of bipolar depression may include other molecules that are not the main focus of this page, including mood stabilizers and antipsychotics with specific evidence. The choice depends on the type of bipolar disorder, phase, maintenance treatments already in use and individual profile. When an antidepressant is used, it should not be considered separately from the risk of activation and the need for appropriate mood stabilizing coverage.
Metabolic monitoring is particularly important because many patients with bipolar disorder receive prolonged treatment and may accumulate cardiovascular risk factors. Efficacy in preventing relapse should be assessed together with weight, blood pressure, glucose or HbA1c and lipids, avoiding a situation in which apparent psychiatric stability masks increasing somatic toxicity.
Quetiapine has the broadest depressive role among the molecules discussed on this page: it has indications for bipolar depression and, in specific extended release formulations, for augmentation of MDD after a suboptimal response. Sedation is common and mainly related to H1 activity, while alpha1 blockade contributes to orthostatic hypotension. Weight gain and glucose and lipid abnormalities require monitoring, especially in patients with obesity, diabetes, dyslipidemia or high cardiovascular risk.
Aripiprazole has a different profile. The risk of weight gain and metabolic disturbance is lower on average than with olanzapine, but akathisia can be highly distressing and should be recognized because it may present as restlessness, intense anxiety or inability to remain still and be mistakenly interpreted as worsening depression. Partial D2 agonism reduces the risk of hyperprolactinemia and, in some cases, can reduce elevated prolactin induced by other antipsychotics.
Olanzapine provides potent antipsychotic activity and specific evidence in psychotic depression when combined with an antidepressant, but has one of the least favorable metabolic profiles in the class. Before prescribing, it is particularly important to document weight or BMI, glucose or HbA1c and lipids and to discuss the risk of increased appetite and weight. Rapid metabolic deterioration requires clinical intervention and may make reassessment of the drug necessary.
Amisulpride at low doses showed efficacy in studies of dysthymia, but these data belong to a literature predating current MDD treatment strategies. It should therefore not be proposed as a modern equivalent of better validated augmentation approaches. Hyperprolactinemia can occur even at low doses and may manifest with galactorrhea, menstrual disturbances, sexual dysfunction, infertility or, over the long term, consequences for bone health.
Levosulpiride is even less supported by contemporary evidence for MDD. Older studies describing antidepressant activity do not allow it to be placed at the same level as strategies now supported by meta analyses and guidelines. Its D2 action carries risks of hyperprolactinemia and extrapyramidal effects; in addition, its gastroenterological use may lead to underestimation of these risks when it is taken for prolonged periods.
Other antipsychotics, such as risperidone or brexpiprazole, have a literature supporting augmentation in MDD in specific international settings. However, European and Italian authorizations do not necessarily coincide with those in the United States. Brexpiprazole, for example, is currently authorized in European information for schizophrenia and should not be presented as a drug approved in Europe for antidepressant augmentation.
None of these molecules should be chosen simply because the patient reports insomnia, anhedonia, apathy or anxiety. Sedation can be a clinically useful effect in some cases but is not synonymous with antidepressant efficacy; similarly, unusual dopaminergic activity is not a biomarker of response. Prescribing should derive from the diagnosis, available evidence and the benefit risk profile.
The safety profile of antipsychotics is strongly molecule specific. Metabolic events include increased appetite, weight gain, hyperglycemia and dyslipidemia; differences among drugs are substantial, with olanzapine among the molecules with the greatest metabolic impact. Neurological effects include akathisia, parkinsonism, dystonia and tardive dyskinesia. Sedation and orthostatic hypotension are particularly relevant with drugs that have H1 and alpha1 activity, while hyperprolactinemia and sexual dysfunction are more likely with marked tuberoinfundibular D2 antagonism.
Before starting an antipsychotic in the context of depression, it is appropriate to record at least weight or BMI, blood pressure and pulse, nutritional status and level of physical activity, fasting glucose or HbA1c and lipid profile. Prolactin should be considered according to the molecule and applicable recommendations; it is particularly relevant in the presence of endocrine symptoms or with high risk drugs. An examination for involuntary movements or other extrapyramidal signs provides a useful baseline for follow up.
NICE recommends, during antipsychotic treatment of depression, monitoring weight weekly for the first 6 weeks, then at 12 weeks, at one year and annually; glucose or HbA1c and lipids are rechecked at 12 weeks, one year and then annually, with greater frequency when risk or abnormal results require it. These intervals provide a clinical framework and do not replace the SmPC for the individual molecule or more intensive protocols in high risk patients.
The ECG is not mandatory indiscriminately for every patient and every antipsychotic, but is indicated when required by the product information, in the presence of heart disease, arrhythmias, syncope, cardiovascular risk factors or combination with other QT prolonging drugs. Electrolyte disturbances, bradycardia and polypharmacy can also increase arrhythmic risk and should be corrected when possible.
Pharmacokinetic interactions are particularly relevant for molecules metabolized by cytochrome P450. Quetiapine depends substantially on CYP3A4: potent inhibitors can increase exposure and potent inducers can reduce it. Aripiprazole is metabolized mainly by CYP2D6 and CYP3A4, so inhibitors and inducers may require dosage adjustments according to the SmPC. Cigarette smoking, through CYP1A2 induction, can reduce olanzapine exposure; abrupt smoking cessation may therefore increase drug levels and require clinical reassessment.
Combination with alcohol, benzodiazepines, opioids or other sedatives can increase somnolence and psychomotor impairment. Combination with other drugs that prolong QT or cause hypotension should be assessed individually. In the presence of fever, rigidity, altered mental status and autonomic instability, the rare but serious neuroleptic malignant syndrome should be considered; persistent involuntary movements may instead indicate tardive dyskinesia and require specialist assessment.
In older adults with psychosis associated with dementia antipsychotics are associated with increased mortality and cerebrovascular events and should not be used as if the risk were equivalent to that in younger adults. During pregnancy and breastfeeding, the decision requires individualized assessment of maternal relapse risk and fetal or neonatal exposure; third trimester exposure may be associated with extrapyramidal or adaptation symptoms in the newborn.
The duration of antipsychotic treatment depends on the indication. In MDD augmentation, therapy should be maintained only if it produces demonstrable clinical benefit and that benefit continues to outweigh the risks. In psychotic depression, continuation for a period after remission may reduce relapse, but duration should be individualized. In bipolar disorder, the maintenance decision depends on the drug, polarity of recurrences and previous response.
Discontinuation should not be abrupt if treatment has been prolonged. Rapid reductions may be followed by insomnia, anxiety, nausea, agitation and return of baseline symptoms; in patients with psychotic or bipolar illness, abrupt discontinuation may also favor relapse. The pace of tapering should be adapted to dose, duration of exposure, clinical vulnerability and emergence of symptoms during dose reduction.
Each follow-up visit should distinguish four dimensions: antidepressant efficacy, possible control of psychotic or bipolar symptoms, subjective adverse effects and objective toxicity. A reduction in the depression score alone is insufficient if the patient develops marked akathisia, rapid weight gain or new onset diabetes. Similarly, mild weight gain may be acceptable if the drug was decisive in severe psychotic depression and metabolic risk is actively managed.
In the presence of partial response, irrational accumulation of psychotropic drugs should be avoided. Each addition should have a defined objective, a time interval for judging efficacy and a monitoring plan. Polypharmacy without a clear clinical hypothesis increases interactions, sedation and metabolic burden and makes it more difficult to attribute benefits and adverse events to individual treatments.
The most appropriate treatment is therefore one in which diagnosis, molecule, dose, formulation and duration are coherent with one another. Speaking generically of “antidepressant neuroleptics” hides substantial differences: quetiapine has specific authorized depressive indications, aripiprazole has strong international evidence for augmentation but a different Italian regulatory status, olanzapine is particularly relevant in psychotic depression but carries high metabolic risk, while amisulpride and levosulpiride have a much more marginal role in modern treatment of MDD.
| Drug | Role in depression | Main concerns |
| Quetiapine | Bipolar depression; specific XR formulations as adjunctive treatment in MDD after a suboptimal response. | Sedation, orthostatic hypotension, weight gain and glucose and lipid abnormalities; CYP3A4 interactions. |
| Aripiprazole | International evidence as augmentation in MDD; effective in bipolar mania but not a standard treatment for acute bipolar depression. | Akathisia and restlessness; antidepressant indication not present in the AIFA SmPCs for ABILIFY reviewed. |
| Olanzapine | Component of combination treatment in psychotic depression; combination with fluoxetine authorized in specific non EU jurisdictions. | High risk of weight gain, dyslipidemia and glycemic abnormalities. |
| Amisulpride | Historical evidence at low doses mainly in dysthymia; not a contemporary standard strategy for MDD. | Hyperprolactinemia even at low doses, extrapyramidal effects and QT effects in predisposed individuals. |
| Levosulpiride | Historical and limited antidepressant literature; not standard augmentation in major modern guidelines. | Hyperprolactinemia, extrapyramidal symptoms and the need to avoid psychiatric use not justified by robust evidence. |
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.